UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.759-760

2017

Volltextzugriff (PDF)

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-07, Vol.34 (1), p.51-58

2011

Volltextzugriff (PDF)

Authors’ response: Importance of defining loss of response before therapeutic drug monitoring

Gut, 2015-08, Vol.64 (8), p.1340-1341

2015

Volltextzugriff (PDF)

Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2013-06, Vol.37 (12), p.1172-1183

2013

Volltextzugriff (PDF)

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD

Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (5), p.499-500

2012

Volltextzugriff (PDF)

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

Alimentary pharmacology & therapeutics, 2012-10, Vol.36 (7), p.650-659

2012

Volltextzugriff (PDF)

Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls

Beneficial microbes, 2012-12, Vol.3 (4), p.287-297

2012

Volltextzugriff (PDF)

Commentary: antibodies reacting with the infliximab Fab portion – something new? Authors' reply

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.552-553

2013

Volltextzugriff (PDF)

Pregnancy Rates and Milk Production in Natural Service and Artificially Inseminated Dairy Herds in Florida and Georgia

Journal of dairy science, 2005-03, Vol.88 (3), p.948-956

2005

Volltextzugriff (PDF)

Comment on ‘Predicting the response to infliximab from trough serum levels’

Gut, 2010-09, Vol.59 (9), p.1298-1299

2010

Volltextzugriff (PDF)

DOP54 Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i124-i126

2023

Volltextzugriff (PDF)

DOP07 Monitoring disease activity by intestinal ultrasound predicts biologic treatment persistence in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i83-i84

2024

Volltextzugriff (PDF)

Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

Clinical gastroenterology and hepatology, 2022-08, Vol.20 (8), p.1671-1686.e16

2022

Volltextzugriff (PDF)

P384 Serum biomarkers of proteolytic type III and type IV collagen remodeling differentiate patients with Inflammatory Bowel Disease according to infliximab treatment response or non-response

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i806-i808

2024

Volltextzugriff (PDF)

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Scandinavian journal of gastroenterology, 2023, Vol.58 (1), p.25-33

2023

Volltextzugriff (PDF)

P068 Recapitulation of human colonocytes in situ by human colon organoids in vitro and after orthotopic transplantation

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i338-i338

2024

Volltextzugriff (PDF)

P242 Immune-cell specific biomarker of early intestinal inflammation: Neutrophil elastase degraded fragment of type III collagen is elevated in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i586-i588

2024

Volltextzugriff (PDF)

P599 Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S545-S546

2021

Volltextzugriff (PDF)

P381 Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S394-S395

2021

Volltextzugriff (PDF)

Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn’s Disease

Journal of Crohn's and colitis, 2015-03, Vol.9 (3), p.238-245

2015

Volltextzugriff (PDF)

P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i441-i441

2022

Volltextzugriff (PDF)

P377 Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S294-S294

2019

Volltextzugriff (PDF)

P744 Therapeutic gain of continued, long-term infliximab therapy in Crohn’s disease patients with response but non-remission after one year of infliximab therapy

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S487-S488

2018

Volltextzugriff (PDF)

P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S409-S409

2017

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Authors’ response: Importance of defining loss of response before therapeutic drug monitoring

Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls

Postoperative complications and waiting time for surgical intervention after radiologically guided drainage of intra-abdominal abscess in patients with Crohn's disease

Commentary: antibodies reacting with the infliximab Fab portion – something new? Authors' reply

Pregnancy Rates and Milk Production in Natural Service and Artificially Inseminated Dairy Herds in Florida and Georgia

Comment on ‘Predicting the response to infliximab from trough serum levels’

DOP54 Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis

DOP07 Monitoring disease activity by intestinal ultrasound predicts biologic treatment persistence in patients with Inflammatory Bowel Disease

Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

P384 Serum biomarkers of proteolytic type III and type IV collagen remodeling differentiate patients with Inflammatory Bowel Disease according to infliximab treatment response or non-response

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

P068 Recapitulation of human colonocytes in situ by human colon organoids in vitro and after orthotopic transplantation

P242 Immune-cell specific biomarker of early intestinal inflammation: Neutrophil elastase degraded fragment of type III collagen is elevated in patients with Inflammatory Bowel Disease

P599 Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study

P381 Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease

Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn’s Disease

P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice

P377 Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease

P744 Therapeutic gain of continued, long-term infliximab therapy in Crohn’s disease patients with response but non-remission after one year of infliximab therapy

P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease

Suchergebnisse filtern